A protease-resistant antimicrobial peptide embedded in nanocellulose wound dressings successfully cleared wound infections in a pig model while promoting healing and showing low toxicity to human skin cells.
Infection eradicatedPLNC8 αβ eliminated wound infection in a pig model while simultaneously promoting re-epithelialization — addressing both infection and healing
What the researchers found
In a porcine (pig) wound infection model, the antimicrobial peptide PLNC8 αβ eradicated wound infections and promoted re-epithelialization (new skin growth over the wound).
Two types of nanocellulose dressings were tested: bacterial cellulose (BC) and wood-derived TEMPO-oxidized nanocellulose (TC). Both showed effective contact killing of bacteria on the dressing surface but were less effective against bacteria floating in wound fluid.
The breakthrough came from incorporating mesoporous silica nanoparticles (MSNs) into the dressings as peptide carriers. MSN-functionalized dressings achieved significantly higher peptide loading and sustained release, resulting in improved antimicrobial efficacy against both surface and suspended bacteria. All formulations showed low cytotoxicity toward human fibroblasts and keratinocytes.
Why it matters
Antibiotic-resistant wound infections are a growing crisis — chronic non-healing wounds affect millions of patients and cost healthcare systems billions annually. Antimicrobial peptides are promising alternatives to antibiotics because bacteria have difficulty developing resistance to them. By embedding a protease-resistant peptide in a wound dressing that slowly releases it, this approach could provide sustained infection control without repeated applications, directly addressing one of the biggest challenges in wound care.
How the study worked
Researchers developed two types of nanocellulose wound dressings (bacterial cellulose and TEMPO-oxidized wood nanocellulose) loaded with the antimicrobial peptide PLNC8 αβ. The peptide was either adsorbed directly onto nanocellulose fibers or encapsulated in mesoporous silica nanoparticles (MSNs) embedded in the dressings. They tested antimicrobial activity against bacteria, cytotoxicity against human primary fibroblasts and keratinocytes, and efficacy in a porcine (pig) wound infection model measuring both bacterial clearance and wound healing (re-epithelialization).
What this study cannot tell us
While the pig wound model is more clinically relevant than mouse models, the study has not been tested in human patients. Specific quantitative data (exact bacterial counts, peptide release rates, healing times) are not provided in the abstract. The study used a single bacterial species or limited range of pathogens — real wound infections often involve mixed bacterial communities. Long-term stability and shelf-life of the functionalized dressings were not addressed.
How to read the evidence
This is a preclinical study combining in vitro cell studies with an in vivo porcine wound model. Pig wound models are considered among the best animal models for human wound healing, which strengthens the translational relevance. However, no human data exists yet for this specific formulation.
When this study was published
Published in 2025, this is a very recent study representing the current state of antimicrobial peptide delivery research. The nanocellulose-MSN delivery platform is a novel approach that has not yet been clinically tested.
The bigger picture
This study sits at the intersection of antimicrobial peptide research, nanotechnology, and wound care — three rapidly advancing fields. The use of mesoporous silica nanoparticles as peptide carriers within a biocompatible wound dressing represents a sophisticated delivery strategy that could be adapted for other therapeutic peptides. As antibiotic resistance continues to escalate, peptide-based wound treatments may become essential clinical tools, and this work demonstrates a practical path from peptide discovery to a functional medical device.
Questions still open
- How would PLNC8 αβ-loaded nanocellulose dressings perform against polymicrobial wound infections with multiple resistant bacterial species?
- What is the shelf life and storage stability of these peptide-functionalized dressings for real-world clinical use?
- Could this mesoporous silica nanoparticle delivery approach be adapted to deliver other therapeutic peptides (e.g., growth factors) to accelerate wound healing further?
Common questions
Why use antimicrobial peptides instead of antibiotics in wound dressings?
What makes PLNC8 αβ special compared to other antimicrobial peptides?
Read the original research
Controlled release of antimicrobial peptides from nanocellulose wound dressings for treatment of wound infections.
Materials today. Bio, 32, 101756
Citation
Zattarin, Elisa; Sotra, Zeljana; Wiman, Emanuel; Bas, Yagmur; Rakar, Jonathan; Berglund, Linn; Starkenberg, Annika; Björk, Emma M; Khalaf, Hazem; Oksman, Kristiina; Bengtsson, Torbjörn; Junker, Johan P E; Aili, Daniel. (2025). Controlled release of antimicrobial peptides from nanocellulose wound dressings for treatment of wound infections.. Materials today. Bio, 32, 101756. https://doi.org/10.1016/j.mtbio.2025.101756